BACKGROUND: Ovarian cancer is the first cause of death among gynecological malignancies with a high incidence of recurrence. Different treatment options are suitable to prolong the survival rate of these patients. Over the last years, one of the most intriguing methods, adopted in different oncologic centers worldwide, is the hyperthermic intraperitoneal chemotherapy (HIPEC). METHODS: A meta-analysis was performed to value the role of HIPEC for ovarian cancer recurrence. Search strategy was conducted with a combination of the following keywords: "ovarian recurrence, ovarian cancer recurrence, peritoneal cancer recurrence, ovarian recurrence AND HIPEC, secondary cytoreduction HIPEC". Seven studies were selected for analysis. RESULTS: In women with recurrent ovarian cancer (ROC), the use of HIPEC in addition to cytoreductive surgery and chemotherapy significantly improved 1-year overall survival (OS) when compared to protocols without HIPEC (OR 2.42; 95% CI, 1.06-5.56; P=0.04; I2=4%). The improvement in OS was maintained significant also after 2, 3 and 5 years respectively (OR 3.33; 95% CI, 1.81-6.10; P<0.01; I2=0%), (OR 4.22; 95% CI, 2.07-8.60; P<0.01; I2=52%), (OR 5.17; 95% CI, 1.40-19.09; P=0.01; I2=82%). CONCLUSIONS: HIPEC seems to have an effective role to prolong survival in patients affected by ROC. 2020 Gland Surgery. All rights reserved.
BACKGROUND: Ovarian cancer is the first cause of death among gynecological malignancies with a high incidence of recurrence. Different treatment options are suitable to prolong the survival rate of these patients. Over the last years, one of the most intriguing methods, adopted in different oncologic centers worldwide, is the hyperthermic intraperitoneal chemotherapy (HIPEC). METHODS: A meta-analysis was performed to value the role of HIPEC for ovarian cancer recurrence. Search strategy was conducted with a combination of the following keywords: "ovarian recurrence, ovarian cancer recurrence, peritoneal cancer recurrence, ovarian recurrence AND HIPEC, secondary cytoreduction HIPEC". Seven studies were selected for analysis. RESULTS: In women with recurrent ovarian cancer (ROC), the use of HIPEC in addition to cytoreductive surgery and chemotherapy significantly improved 1-year overall survival (OS) when compared to protocols without HIPEC (OR 2.42; 95% CI, 1.06-5.56; P=0.04; I2=4%). The improvement in OS was maintained significant also after 2, 3 and 5 years respectively (OR 3.33; 95% CI, 1.81-6.10; P<0.01; I2=0%), (OR 4.22; 95% CI, 2.07-8.60; P<0.01; I2=52%), (OR 5.17; 95% CI, 1.40-19.09; P=0.01; I2=82%). CONCLUSIONS: HIPEC seems to have an effective role to prolong survival in patients affected by ROC. 2020 Gland Surgery. All rights reserved.
Authors: Stefano Cianci; Carlo Ronsini; Giuseppe Vizzielli; Alessandro Tropea; Antonio Biondi; Giovanni Scambia; Anna Fagotti Journal: Updates Surg Date: 2018-11-08
Authors: Philipp Harter; Bianca Beutel; Piero F Alesina; Dietmar Lorenz; Andre Boergers; Florian Heitz; Rita Hils; Christian Kurzeder; Alexander Traut; Andreas du Bois Journal: Gynecol Oncol Date: 2014-01-23 Impact factor: 5.482
Authors: Daniel Ren Yi Yap; Jolene Si Min Wong; Qiu Xuan Tan; Joey Wee-Shan Tan; Claramae Shulyn Chia; Chin-Ann Johnny Ong Journal: Front Oncol Date: 2021-12-03 Impact factor: 6.244
Authors: Elisabeth K Petersen; Mats Bue; Christina Harlev; Andrea R Jørgensen; Anne Schmedes; Pelle Hanberg; Lone K Petersen; Maiken Stilling Journal: Pleura Peritoneum Date: 2022-06-06
Authors: Philipp Horvath; Can Yurttas; Stefan Beckert; Alfred Königsrainer; Ingmar Königsrainer Journal: Cancers (Basel) Date: 2021-05-19 Impact factor: 6.639
Authors: Thamer A Bin Traiki; Sulaiman A AlShammari; Wadha S AlOtaibi; Shahad N AlAnazi; Mashal M Alnmry; Abdullah M Albdah; Noura S Alhassan Journal: Ann Med Surg (Lond) Date: 2021-06-03